Physician profile
Satish Iduru
NPI 1417045311
$6,114.69
in general payments reported to CMS, 2019-2025
37 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $586 · 2021: $940 · 2022: $749 · 2023: $681 · 2024: $1,320 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,039.06 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $824.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $729.29 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $408.71 | 2022-2025 | Ibsrela, Xphozah 30 Mg |
| Redhill Biopharma INC. | $235.66 | 2020-2022 | |
| Medtronic, INC. | $197.04 | 2021-2024 | Interstim, Bravo |
| Pfizer INC. | $190.93 | 2023-2025 | |
| Evoke Pharma, INC. | $159.83 | 2022-2025 | Gimoti |
| Phathom Pharmaceuticals, INC. | $157.96 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $105.43 | 2023-2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $95.93 | 2021 | |
| Janssen Biotech, INC. | $90.57 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $89.22 | 2019-2022 | |
| Celgene Corporation | $80.33 | 2022-2024 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $76.50 | 2024 | |
| Braintree Laboratories, INC. | $75.03 | 2019-2023 | Suflave, Sutab |
| Gilead Sciences, INC. | $73.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $72.77 | 2024 | Andexxa |
| Aimmune Therapeutics, INC. | $56.34 | 2023-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $39.30 | 2022 | |
| Novo Nordisk INC | $38.44 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $34.90 | 2024-2025 | Terlivaz |
| Qol Medical, LLC | $29.13 | 2022 | |
| Olympus America INC. | $24.73 | 2024 | Endoclot Phs |
| Alnylam Pharmaceuticals INC. | $24.28 | 2021 | |
| Merck Sharp & Dohme LLC | $20.17 | 2022 | |
| Intercept Pharmaceuticals, INC. | $19.81 | 2020 | |
| Concordia Pharmaceuticals INC. | $18.78 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.25 | 2021 | |
| Mauna Kea Technologies, INC. | $17.18 | 2024 | |
| Endo Pharmaceuticals INC. | $16.02 | 2019 | |
| Endogastric Solutions, INC | $2.95 | 2023 | Esophyx |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Iduru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.